JP2019536734A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536734A5
JP2019536734A5 JP2019506697A JP2019506697A JP2019536734A5 JP 2019536734 A5 JP2019536734 A5 JP 2019536734A5 JP 2019506697 A JP2019506697 A JP 2019506697A JP 2019506697 A JP2019506697 A JP 2019506697A JP 2019536734 A5 JP2019536734 A5 JP 2019536734A5
Authority
JP
Japan
Prior art keywords
region
domain
fusion protein
heterodimer
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019506697A
Other languages
English (en)
Japanese (ja)
Other versions
JP6993403B2 (ja
JP2019536734A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from KR1020170101594A external-priority patent/KR102050463B1/ko
Priority claimed from PCT/KR2017/008676 external-priority patent/WO2018030806A1/ko
Publication of JP2019536734A publication Critical patent/JP2019536734A/ja
Publication of JP2019536734A5 publication Critical patent/JP2019536734A5/ja
Application granted granted Critical
Publication of JP6993403B2 publication Critical patent/JP6993403B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019506697A 2016-08-10 2017-08-10 ヘテロダイマーFc融合サイトカインおよびそれを含む医薬組成物 Active JP6993403B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2016-0101823 2016-08-10
KR20160101823 2016-08-10
KR10-2017-0101594 2017-08-10
KR1020170101594A KR102050463B1 (ko) 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
PCT/KR2017/008676 WO2018030806A1 (ko) 2016-08-10 2017-08-10 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021033816A Division JP7111855B2 (ja) 2016-08-10 2021-03-03 ヘテロダイマーFc融合サイトカインおよびそれを含む医薬組成物

Publications (3)

Publication Number Publication Date
JP2019536734A JP2019536734A (ja) 2019-12-19
JP2019536734A5 true JP2019536734A5 (enExample) 2020-09-24
JP6993403B2 JP6993403B2 (ja) 2022-03-03

Family

ID=61524969

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019506697A Active JP6993403B2 (ja) 2016-08-10 2017-08-10 ヘテロダイマーFc融合サイトカインおよびそれを含む医薬組成物
JP2021033816A Active JP7111855B2 (ja) 2016-08-10 2021-03-03 ヘテロダイマーFc融合サイトカインおよびそれを含む医薬組成物
JP2022116329A Active JP7488854B2 (ja) 2016-08-10 2022-07-21 ヘテロダイマーFc融合サイトカインおよびそれを含む医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021033816A Active JP7111855B2 (ja) 2016-08-10 2021-03-03 ヘテロダイマーFc融合サイトカインおよびそれを含む医薬組成物
JP2022116329A Active JP7488854B2 (ja) 2016-08-10 2022-07-21 ヘテロダイマーFc融合サイトカインおよびそれを含む医薬組成物

Country Status (14)

Country Link
US (4) US10696722B2 (enExample)
EP (2) EP4470552A3 (enExample)
JP (3) JP6993403B2 (enExample)
KR (4) KR102050463B1 (enExample)
CN (1) CN110267977A (enExample)
AU (2) AU2017310163B2 (enExample)
BR (1) BR112019002394B1 (enExample)
CA (1) CA3033475A1 (enExample)
DK (1) DK3511340T3 (enExample)
ES (1) ES3000558T3 (enExample)
IL (1) IL264692B2 (enExample)
MX (2) MX386014B (enExample)
SG (1) SG11201901071TA (enExample)
ZA (1) ZA201900772B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3000558T3 (en) 2016-08-10 2025-02-28 Univ Ajou Ind Academic Coop Found Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
CA3069105A1 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
KR102285557B1 (ko) 2018-02-14 2021-08-04 주식회사 엘지화학 촉매의 충진방법 및 이를 이용한 부타디엔의 제조방법
CN110396133B (zh) * 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins
CA3157024A1 (en) * 2019-10-03 2021-04-08 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
IL297495A (en) * 2020-04-22 2022-12-01 Dragonfly Therapeutics Inc Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins
JP2024500354A (ja) 2020-12-10 2024-01-09 インベンラ, インコーポレイテッド ヘテロ二量体化のための直交変異
AU2022369312A1 (en) * 2021-10-20 2024-05-02 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof
KR102796245B1 (ko) * 2022-05-10 2025-04-18 아주대학교산학협력단 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins
EP4612165A1 (en) * 2022-11-02 2025-09-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
CN119768414A (zh) * 2022-11-10 2025-04-04 康立泰生物医药(青岛)有限公司 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用
WO2024249320A1 (en) * 2023-05-26 2024-12-05 University Of Florida Research Foundation, Incorporated In vivo optimization of biologics
CN117986386B (zh) * 2024-02-06 2024-11-29 康立泰生物医药(青岛)有限公司 重组人白细胞介素-35及其制备方法和应用

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US20020055488A1 (en) 2000-09-21 2002-05-09 Wessels Michael R. Prevention and treatment of streptococcal and staphylococcal infection
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
WO2005114186A1 (ja) 2004-05-20 2005-12-01 Wako Pure Chemical Industries, Ltd. ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
US8163498B2 (en) 2006-08-08 2012-04-24 Seikagaku Corporation Method for determination of molecular weight of hyaluronic acid
WO2008089448A2 (en) 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
SG189730A1 (en) 2008-04-02 2013-05-31 Macrogenics Inc Her2/neu-specific antibodies and methods of using same
ES2399584T3 (es) 2008-04-15 2013-04-02 Wako Pure Chemical Industries, Ltd. Nueva proteína capaz de unirse al ácido hialurónico y procedimiento para medir el ácido hialurónico usando la misma
BRPI1007005A2 (pt) 2009-01-29 2016-03-22 Medimmune Llc anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
AU2010233994A1 (en) 2009-04-07 2011-09-22 Roche Glycart Ag Bispecific anti-ErbB-3/anti-c-Met antibodies
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
DK2560683T4 (da) 2010-04-23 2022-08-29 Hoffmann La Roche Fremstilling af heteromultimeriske proteiner
CA2807278A1 (en) 2010-08-24 2012-03-01 F. Hoffmann - La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012032080A1 (en) 2010-09-07 2012-03-15 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Stabilised human fc
SG10201508401TA (en) 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
LT2647707T (lt) 2010-11-30 2018-11-12 Chugai Seiyaku Kabushiki Kaisha Citotoksiškumą indukuojantis terapinis agentas
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
LT3075745T (lt) 2011-02-10 2018-11-26 Roche Glycart Ag Mutavę interleukino-2 polipeptidai
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
PL2714718T3 (pl) 2011-05-24 2017-11-30 Symic Ip, Llc Syntetyczne peptydoglikany wiążące kwas hialuronowy, otrzymywanie i sposoby zastosowania
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
CA3101783C (en) 2011-10-11 2023-01-31 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
EP2804586A4 (en) 2012-01-19 2016-03-16 Univ Johns Hopkins BIOMATERIALS CONTAINING HYALURONIC ACID BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMERMOLUCKS FOR HYALURONIC ACIDIC TREATMENT AND TISSUE RENEWAL APPLICATIONS
ES2743399T3 (es) 2012-04-20 2020-02-19 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
WO2013163766A1 (en) 2012-05-04 2013-11-07 Cangene Corporation ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC
KR20150038511A (ko) 2012-08-02 2015-04-08 에프. 호프만-라 로슈 아게 불활성 면역글로불린 Fc-영역을 갖는 Fc-융합체로서의 가용성 FcR 의 생산 방법 및 그의 용도
RU2015106812A (ru) 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
AU2013301582B2 (en) 2012-08-07 2018-09-06 Roche Glycart Ag Composition comprising two antibodies engineered to have reduced and increased effector function
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
DK2927321T3 (da) * 2012-11-27 2021-03-15 Univ Ajou Ind Academic Coop Found Ch3-domæne-variantpar der inducerer dannelse af heterodimer af tungkæde konstant region af antistof ved høj effektivitet, fremgangsmåde til fremstilling af samme, og anvendelse deraf
CA3093606A1 (en) * 2013-03-15 2014-09-18 Xencor, Inc. Heterodimeric proteins for induction of t cells
EA035645B1 (ru) 2013-03-15 2020-07-21 Дженентек, Инк. ПОЛИПЕПТИДЫ IL-22, ХИМЕРНЫЕ БЕЛКИ IL-22 Fc И ИХ ПРИМЕНЕНИЕ
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
EP2970435B1 (en) 2013-03-15 2020-08-12 Eli Lilly and Company Methods for producing fabs and bi-specific antibodies
KR102266819B1 (ko) 2013-04-29 2021-06-18 에프. 호프만-라 로슈 아게 Fc-수용체 결합 개질된 비대칭 항체 및 이의 사용 방법
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
ES2955736T3 (es) 2014-05-06 2023-12-05 Hoffmann La Roche Producción de proteínas heteromultiméricas usando células de mamífero
KR101721295B1 (ko) 2014-06-11 2017-04-10 주식회사 엘지화학 염화비닐계 수지의 제조방법
US10519234B2 (en) 2014-06-27 2019-12-31 Innate Pharma NKp46 binding proteins
EP3215524B1 (en) 2014-11-06 2021-01-13 F.Hoffmann-La Roche Ag Fc-region variants with modified fcrn- and protein a-binding properties
SI3215528T1 (sl) 2014-11-06 2019-11-29 Hoffmann La Roche Variante regije Fc s spremenjeno vezavo FcRn in postopki uporabe
CN104628870A (zh) * 2015-02-04 2015-05-20 中国药科大学 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白
JP6898303B2 (ja) 2015-08-07 2021-07-07 エーエルエックス オンコロジー インコーポレイテッド Sirp−アルファドメインまたはそのバリアントを有する構築物
CA3001185A1 (en) 2015-10-06 2017-04-13 Regents Of The University Of Minnesota Nk engaging compounds and methods
KR101851380B1 (ko) 2015-10-12 2018-04-23 아주대학교산학협력단 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
WO2018030806A1 (ko) 2016-08-10 2018-02-15 아주대학교산학협력단 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
ES3000558T3 (en) 2016-08-10 2025-02-28 Univ Ajou Ind Academic Coop Found Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
KR101928981B1 (ko) 2016-09-02 2018-12-13 고려대학교 산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
CN110214148A (zh) 2016-10-14 2019-09-06 Xencor股份有限公司 含有IL-15/IL-15Rα Fc融合蛋白和PD-1抗体片段的双特异性异源二聚体融合蛋白
ES2955074T3 (es) 2017-02-20 2023-11-28 Dragonfly Therapeutics Inc Proteínas que se unen a HER2, NKG2D Y CD16
AU2018241624B2 (en) 2017-03-27 2024-01-25 F. Hoffmann-La Roche Ag Improved antigen binding receptors
CA3062519A1 (en) 2017-05-11 2018-11-15 Emd Millipore Corporation Method of maintaining narrow residence time distributions in continuous flow systems using solid material packet interfaces
MX2019013517A (es) 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
US11426706B2 (en) 2017-06-21 2022-08-30 Cephalon, Inc. Cation exchange chromatography wash buffer
JP2019014449A (ja) 2017-07-10 2019-01-31 トヨタ自動車株式会社 車両用動力伝達装置
CN113004417A (zh) 2017-09-07 2021-06-22 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN111132997A (zh) 2017-09-21 2020-05-08 默克专利有限公司 包含fgf-18部分的融合蛋白
MY202919A (en) 2017-09-22 2024-05-29 Wuxi Biologics Ireland Ltd Novel bispecific polypeptide complexes
CN111246885B (zh) 2017-10-20 2024-06-11 豪夫迈·罗氏有限公司 从单特异性抗体生成多特异性抗体的方法
BR112021000392A2 (pt) 2018-07-11 2021-04-06 Momenta Pharmaceuticals, Inc. Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados
SG11202103192RA (en) 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
AU2019366956B2 (en) 2018-10-23 2025-10-30 Dragonfly Therapeutics, Inc. Heterodimeric Fc-fused proteins

Similar Documents

Publication Publication Date Title
JP2019536734A5 (enExample)
Fan et al. Bispecific antibodies and their applications
ES2991459T3 (es) Ligantes de albúmina sérica mejorados
ES2752248T3 (es) Heterodímero proteínico y uso del mismo
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
JP6669722B2 (ja) Cd3結合ドメイン
JP5906233B2 (ja) 抗ErbB3抗体
US20110189203A1 (en) Immunoglobulin constructs
JP2016188209A5 (enExample)
JP2020521448A5 (enExample)
JP2019536430A5 (enExample)
EA201991099A1 (ru) Антитела против cd73 и их применение
JP2020508997A5 (enExample)
KR20210030503A (ko) Nkg2d, cd16 및 종양-연관 항원에 결합하는 단백질
JP2022512043A (ja) 合理的に設計された新規なタンパク質組成物
JP2019535763A5 (enExample)
JP2009114201A5 (enExample)
TW200932263A (en) Antibodies that bind IL-4 and/or IL-13 and their uses
JP2016508153A5 (enExample)
WO2014144299A2 (en) DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα
TW201333033A (zh) 雙可變域免疫球蛋白及其用途
JP2020514277A5 (enExample)
IL274071B1 (en) Method for in vivo generation of multispecific antibodies from monospecific antibodies
US20140213771A1 (en) Multi-specific binding proteins
WO2020076969A3 (en) Anti-lap antibody variants and uses thereof